Related Experiment Video
Updated: Apr 11, 2026
04:22
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
1.3K
Oral suspension versus tablet sildenafil for erectile dysfunction: a prospective multicenter comparative study on
Borja García-Gómez1,2, Manuel Alonso-Isa1,2, Esther García-Rojo2
1Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain.
International Journal of Impotence Research
|April 9, 2026
Summary
Sildenafil oral suspension (SiSUS) shows comparable efficacy to sildenafil tablets (SiTAB) for erectile dysfunction (ED). SiSUS offers a faster onset of action and greater patient satisfaction, particularly in men 65 and younger.
Area of Science:
- Urology
- Pharmacology
- Men's Health
Background:
- New sildenafil formulations aim to improve treatment efficacy and patient experience for erectile dysfunction (ED).
- Oral suspension offers potential advantages in onset of action and acceptability over traditional tablets.
Purpose of the Study:
- To compare the efficacy, safety, and patient satisfaction of sildenafil oral suspension (SiSUS) versus sildenafil tablets (SiTAB) in treatment-naïve men with ED.
Main Methods:
- Prospective, non-randomized, multicenter observational study involving 133 treatment-naïve men with ED.
- Patients received either SiSUS or SiTAB for eight weeks.
- Outcomes included patient satisfaction (EDITS), erectile function (IIEF-15), erection latency, and adverse events.
Main Results:
- Both SiSUS and SiTAB significantly improved IIEF-15 scores.
- Patient satisfaction (EDITS) was similar overall but significantly higher for SiSUS in men ≤65 years.
- SiSUS demonstrated a significantly faster onset of action (30 min vs. 60 min).
- Adverse event rates were comparable between groups.
Conclusions:
- Sildenafil oral suspension provides similar efficacy and safety to sildenafil tablets for ED treatment.
- SiSUS offers a faster onset and enhanced satisfaction, especially in younger patients (≤65).
- SiSUS represents a valuable option for individualized ED management.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
762
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
762
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
351
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
351
01:26Oral Drug Delivery Systems: Continuous-Release Systems
247
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
247
01:23Oral Drug Delivery Systems: Introduction
236
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
236
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
405
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
405
01:11Oral Drug Delivery Systems: Delayed-Release Systems
155
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
155